Q2 FY26 Quarterly Activities Report and Appendix 4C
| Stock | Dubber Corporation Ltd (DUB.ASX) |
|---|---|
| Release Time | 28 Jan 2026, 8:35 a.m. |
| Price Sensitive | Yes |
Q2 FY26 Quarterly Activities Report and Appendix 4C
- Targeting underlying operating run-rate cashflow breakeven in FY26
- New agreement signed with one of North America's largest CSPs, expected to receive AUD$4.6m upfront payment in Q3 FY26
- Continued focus on revenue growth, cost optimization, and operational efficiencies
Dubber Corporation Ltd released its Q2 FY26 quarterly activities report and Appendix 4C. Key highlights include the company targeting underlying operating run-rate cashflow breakeven in FY26, a new agreement signed with one of North America's largest CSPs worth an expected AUD$4.6m upfront payment in Q3 FY26, and continued focus on revenue growth, cost optimization, and operational efficiencies. The company reported Q2 FY26 recurring revenue of $7.8m, down from $8.2m in the prior quarter, but total cash-based costs reduced by 12% compared to Q1 FY26. Dubber also provided updates on its brand consolidation, go-to-market strategy, and product development roadmap. The company continues to pursue recovery of funds through legal proceedings against former auditors and executives. Overall, Dubber is focused on delivering on its growth plans and achieving cashflow breakeven during FY26 through a combination of revenue growth, cost reductions, and platform optimization.
Targeting underlying operating run-rate cashflow breakeven in FY26. The company expects to receive an upfront payment of approximately AUD$4.6m in Q3 FY26 under a new agreement with a Tier 1 North American CSP.
Dubber is focused on delivering on its growth plans and achieving cashflow breakeven during FY26 through a combination of revenue growth, cost reductions, and platform optimization. The company is uplifting customers to its AI products, improving marketing and sales, automating business processes, and evolving its product suite to increase value for end customers.